Market Overview

Bernstein Says Generic Copaxone Win Could Help Momenta Break through $20 Level

Related MNTA
Supreme Court Denies Teva's Request - Analyst Blog
Mid-Morning Market Update: Markets Rise; Halliburton Posts Q1 Profit
Related TEVA
Will Eli Lilly (LLY) Keep Its Earnings Streak Alive? - Analyst Blog
AxoGen (AXGN) in Focus: Stock Moves 5.7% Higher - Tale of the Tape
Pfizer Loses Bid to Hold Celebrex Exclusivity to '15 (Fox Business)

Momenta Pharmaceuticals (NASDAQ: MNTA) shares spiked sharply Friday following news of a legal ruling invalidating Teva Pharmaceutical's (NYSE: TEVA) patents on Copaxone in 2015 and partly invalidating its 2014 patents.

Bernstein analyst Ronny Gal sees a 75 percent chance of the court decision being favorable for Momenta. The ruling could open the door to Momenta introducing a generic Copaxone within the next few months, according to Gal.

If Momenta is able to introduce the first generic Copaxone by May 2014, Gal believes shares could be valued at $30. This is nearly twice the $15.35 level shares were trading at prior to Friday's spike.

Gal believes a later release by Q4 2015 could spell upside of 30 percent from current levels to $23 per share.

Gal rates Momenta at Outperform with a $20 price target.

Posted-In: Analyst Color News FDA Legal Analyst Ratings Movers

 

Most Popular

Related Articles (MNTA + TEVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free